by Manon FRACHON | 15 Nov Wed | English
Jeito Capital’s second round of funding will support NMD Pharma in becoming a leading, global, clinical-stage company, with a strong pipeline of breakthrough therapies for patients suffering from severe neuromuscular disorders. This funding round will also contribute...
by Manon FRACHON | 14 Nov Tue | English
EyeBio doubles the size of its original Series A raise with an additional $65 million, with new investors Bain Capital Life Sciences, Omega Funds and Vertex Ventures HC joining the round to support accelerated development of its innovative retinal disease pipeline...
by Manon FRACHON | 12 Sep Tue | English
Paris, France, September 11th 2023 – Three years after being the 1st biopharma fund to be awarded the Tibi 1 label, Jeito Capital has announced that it has been renewed in the Tibi 2 selection, confirming its role as an accelerator in the financing of technology...
by Manon FRACHON | 7 Sep Thu | English
Jeito Capital co-leads oversubscribed financing Corteria, a late preclinical stage company, is developing first-in-class therapies with promising novel approaches for unaddressed heart failure subpopulations, addressing high unmet medical needs Jeito Capital marks its...
by Manon FRACHON | 13 Apr Thu | English
Funds will support the Phase I/II clinical development of Alentis’ two first-in-class anti-Claudin-1 (CLDN1) antibodies for organ fibrosis and CLDN1 positive tumors, and CLDN1 platform development After its investment 2 years ago, Jeito Capital amplifies its...
Recent Comments